Infectious diseases and antibiotic resistance are an ever-present threat worldwide, and LAB-Net wants to be at the forefront of reducing its global burden. Our key contributor in this fight is our expertise and warm-base network of laboratories.
In order to further develop our expertise, we published a tender from which Deloitte was selected. The business strategy company is supporting us in the growth of LAB-Net. Deloitte will evaluate the performance of LAB-Net since the launch in 2013, assess the current market, help us to define market opportunities and finalize our new and improved business plan.
Laboratories are the pillars of our network, therefore we highly value your opinion. We want to know how you feel about LAB-Net and what we can do to better serve and support you. Deloitte will contact a number of our laboratories to do personal interviews. In addition, we will send out a questionnaire to a larger group of laboratory partners to further inquire on this matter. We warmly invite you to share your thoughts.
LAB-Net will continue to evolve, but our core activities remain the same:
· research services - from protocol development, the provision of sample kits to final analysis
· support in the development, evaluation and appropriate application of diagnostic tests
· our unique biobank -collection, storage and sharing of specimens and associated data
· the creation of new partnerships
If you want to know more about LAB-Net, feel free to contact us!